- Home
- RNA
as 04-18-2025 1:42pm EST
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 3.2B | IPO Year: | 2020 |
| Target Price: | $68.25 | AVG Volume (30 days): | 1.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.89 | EPS Growth: | N/A |
| 52 Week Low/High: | $21.51 - $56.00 | Next Earning Date: | 05-08-2025 |
| Revenue: | $10,897,000 | Revenue Growth: | 13.98% |
| Revenue Growth (this year): | -41.07% | Revenue Growth (next year): | 135.33% |
Stock Insider Trading Activity of Avidity Biosciences Inc. (RNA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Gallagher Kathleen P. | RNA | Chief Program Officer | Apr 1 '25 | Sell | $27.83 | 5,875 | $163,485.98 | 50,554 | |
| Boyce Sarah | RNA | President and CEO | Mar 20 '25 | Sell | $31.06 | 31,540 | $979,563.01 | 305,871 | |
| MacLean Michael F | RNA | Chief Financial Officer | Mar 20 '25 | Sell | $31.06 | 7,935 | $246,424.60 | 96,720 | |
| Flanagan W. Michael | RNA | Chief Scientific Officer | Mar 20 '25 | Sell | $31.06 | 11,780 | $365,867.95 | 80,195 | |
| McCarthy Teresa | RNA | Chief Human Resources Officer | Mar 20 '25 | Sell | $31.06 | 7,778 | $241,583.12 | 97,130 | |
| Hughes Steven George | RNA | Chief Medical Officer | Mar 20 '25 | Sell | $31.06 | 9,578 | $297,490.76 | 72,850 | |
| Flanagan W. Michael | RNA | Chief Scientific Officer | Mar 11 '25 | Sell | $30.13 | 20,000 | $602,614.00 | 80,195 | |
| Gallagher Kathleen P. | RNA | Chief Program Officer | Mar 3 '25 | Sell | $29.41 | 5,875 | $172,807.25 | 50,554 | |
| Gallagher Kathleen P. | RNA | Chief Program Officer | Feb 3 '25 | Sell | $32.16 | 5,875 | $188,918.26 | 50,554 | |
| Boyce Sarah | RNA | President and CEO | Jan 21 '25 | Sell | $28.59 | 10,397 | $297,291.42 | 305,871 |
Latest Avidity Biosciences Inc. News
RNA Breaking Stock News: Dive into RNA Ticker-Specific Updates for Smart Investing
MT Newswires
11 days ago
Avidity Says Japan Grants Orphan Drug Status to Del-Desiran for Myotonic Dystrophy Type 1
PR Newswire
11 days ago
Avidity Biosciences Receives Orphan Drug Designation in Japan for Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1
Insider Monkey
14 days ago
Avidity Biosciences (RNA): Among Unstoppable Stocks That Could Double Your Money
Zacks
16 days ago
Avidity Biosciences (RNA) Soars 11.3%: Is Further Upside Left in the Stock?
TipRanks
18 days ago
Biotech stocks slide as Marks resignation seen being negative for sector
PR Newswire
18 days ago
Avidity Biosciences to Participate in Upcoming Investor Conference
MT Newswires
19 days ago
Avidity Completes Enrollment in Del-brax Trial's Biomarker Group for Facioscapulohumeral Muscular Dystrophy
PR Newswire
19 days ago
Avidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax) in People Living with Facioscapulohumeral Muscular Dystrophy
Compare RNA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RNA Avidity Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.